FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi